|
Uveal melanoma drug enters phase II trials |
|
Thursday, 22 November 2007 |
Phase II clinical trials of a new injectable drug designed to treat metastatic malignant uveal melanoma have been launched in the US.
Hana Biosciences said that the goal of the trial is to examine the efficacy of Marqibo Optisome, with the firm also collecting data regarding the safety and anti-tumour activity of the drug. |
|
Read more...
|
|
|
Phase II CAP drug trials to begin |
|
Thursday, 22 November 2007 |
Multi-national phase II trials of a new antibiotic for the treatment of community-acquired pneumonia (CAP) in adult patients are set to begin soon, it has been announced.
CAP is a disease which causes the lung tissue to become inflamed after exposure to germs in the course of a patient's daily life. |
|
Read more...
|
|
|
CMV disease drug gets orphan approval |
|
Thursday, 22 November 2007 |
The European Medicines Agency has granted orphan drug designation to a drug designed to prevent patients with impaired cell-mediated immunity from developing cytomegalovirus (CMV) disease.
Drug maker ViroPharma said that Camvia, an oral drug currently being studied in phase III clinical trials, had won the European nod after it had been granted orphan drug designation in the US by the Food and Drug Administration. |
|
Read more...
|
|
|
Ulcerative colitis medicine to undergo new trials |
|
Thursday, 22 November 2007 |
Worldwide phase IIb trials of a drug designed to provide an alternative treatment option for patients suffering from mild-to-moderate ulcerative colitis are to be launched, it has been revealed.
The condition causes the bowel to become inflamed and can vary in severity, with some patients having to live with repeated flare-ups for a number of years. |
|
Read more...
|
|
|
|
<< Start < Prev 1 2 3 Next > End >>
|
| Results 49 - 57 of 57 |
